PAB.AX - Patrys Limited
ASX - ASX Delayed price. Currency in AUD
At close: 02:04PM AEST
Stock chart is not supported by your current browser
| Previous close | 0.0110 |
| Open | 0.0120 |
| Bid | 0.0110 x 166154000 |
| Ask | 0.0120 x 165000000 |
| Day's range | 0.0110 - 0.0120 |
| 52-week range | 0.0100 - 0.0340 |
| Volume | |
| Avg. volume | 3,073,917 |
| Market cap | 22.63M |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings date | 28 Aug 2023 - 01 Sept 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WirePatrys Appoints Global Biotechnology Leader as Chairman - In Preparation for First Clinical Trial for Groundbreaking Cancer Therapy
MELBOURNE, Australia, November 18, 2022--Patrys Limited (ASX: PAB, "Patrys" or the "Company"), a therapeutic antibody development company, has announced the appointment of Dr. Charmaine Gittleson as the Chairman of the Board of Directors – a highly respected and experienced global biotechnology leader.